WO2012105872A1 - Гомо- и гетеро-полиаминокислотные производные фуллерена с60, способ их получения и фармацевтические композиции на их основе - Google Patents
Гомо- и гетеро-полиаминокислотные производные фуллерена с60, способ их получения и фармацевтические композиции на их основе Download PDFInfo
- Publication number
- WO2012105872A1 WO2012105872A1 PCT/RU2012/000062 RU2012000062W WO2012105872A1 WO 2012105872 A1 WO2012105872 A1 WO 2012105872A1 RU 2012000062 W RU2012000062 W RU 2012000062W WO 2012105872 A1 WO2012105872 A1 WO 2012105872A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fullerene
- derivatives
- amino acids
- drug
- polyamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2604/00—Fullerenes, e.g. C60 buckminsterfullerene or C70
Definitions
- the invention relates to the pharmaceutical industry and medicine, in particular to new homo- and hetero-polyamino acid derivatives of C 6 fullerene of formula (I), as well as to a process for their preparation and creation of pharmaceutical compositions based on them.
- fullerene derivatives in medicine is based on the lipophilic properties of the fullerene nucleus, allowing fullerene derivatives to penetrate cell membranes, and the ability of fullerene to generate singlet oxygen, which breaks down DNA, with a high quantum yield. These properties provide functional fullerene derivatives with cytotoxic, antiviral, and other properties (Bedrov D., Smith GD, Davande N., "Passive transport of fullerenes through a lipid membrane.” J. Pharm. Chem., B, 2008, v .
- a promising method for producing water-soluble fullerene compositions is the chemical modification of the sphere fullerene by the introduction of hydrophilic solubilizing ligands.
- International application WO2005 / 070827 presents a series of amino acid derivatives of fullerene obtained by the reaction of cycloaddition of amino acid fragments to fullerene and the products of their incorporation into biologically active organic substrates.
- the synthesis methods presented in this technical solution are multi-stage and non-technological. The resulting compounds have low solubility in water.
- Analogues of the present invention are compounds and methods for their preparation described in international application WO2009 / 00203, as well as RF patent JY "2236852.
- SUBSTITUTE SHEET (RULE 26) equimolar addition of amino acids to fullerene followed by the replacement of active hydrogen with an organic biologically active ligad to form compounds of the type.
- the obtained compounds have inhibitory activity against tumor metastases, enhance the antileukemic activity of cyclophosphamide, and may be suitable as donors of nitric oxide or as quick-acting vasodilators for antihypertensive therapy.
- the main disadvantage of the compounds of this application is that they are products of covalent attachment, contain a small amount of polar groups and have a low solubility in water.
- fullerene polycarboxylic anions of the general formula C 6 oH n [NH (CH 2 ) m C (0) 0 " ] n, where C 60 is the fullerene core, NH ( CH 2 ) m C (0) 0 " is an aminocarboxylic anion; m is an integer from 1 to 5, n is an integer from 2 to 12.
- an amino acid in the form of a salt (potassium or sodium) is added to a solution of fullerene in o-dichlorobenzene (toluene or any other organic solvent), then a solubilizer is added.
- a solubilizer various polyalkylene oxides are used: polyethylene glycol whether they say. masses from 150 to 400, and above 400 (for example, PEG-1500), as well as polyethylene glycol dimethyl ether mol. mass 500.
- any strong reducing agent (alkali metals) is added.
- the ratio of fullerene to amino acids increased by more than 50 times.
- water-insoluble fullerene polycarboxylic acid is converted to more preferred pharmaceutically acceptable salts, such as the sodium salt, which are soluble in water.
- the addition of a salt of weak volatile acid occurs by treating the solution with a salt of an alkali metal and weak volatile acid. When the solution is concentrated by evaporation or lyophilization, the weak acid is removed, and fullerene polycarboxylic acids are released in the form of their alkali metal salts.
- the target product according to this invention is characterized by a constant composition, the content in the target product of the main substance is only 87.8%.
- the description does not contain any technological regulations related to determining the optimal amounts of the starting compounds, the ratios of the amounts of solvents used, and, especially, the description of the methods for isolating the desired compounds.
- fullerene amino acid derivatives obtained by the production method presented in the patent are that this method produces a mixture of fullerene carboxylate anions, both salt and acid forms. Get an individual connection by the method described in the patent, does not seem possible. Also, fullerene polyamino acids obtained by the patented method in the acid form are practically insoluble in water. It was not possible to obtain a stable pharmaceutical composition with fullerene polycarboxylic anions, because during storage, the compounds precipitate.
- the method uses freshly prepared anhydrous potassium salts of amino acids in a finely divided state, and the precipitation of the solid precipitate of potassium salts of fullerene polyamino acids is carried out by filtration, washing with ethyl alcohol and drying.
- fullerene polyamino acids of the specified composition can only be obtained using freshly prepared anhydrous potassium salts of amino acids.
- the interfacial catalyst methyl esters of polyethylene oxides of molecular weight 200, 400, 500 are used.
- compositions containing, as active substance, homo- and hetero-polyamino acid derivatives of fullerene of the formula (II), having activity against herpes virus, hepatitis C virus, influenza viruses of various nature, HIV, as well as anti - tumor and anti-psoriatic activity.
- the pharmaceutical compositions may be in the form of tablets, capsules, ointments, emulsions, suppositories, solutions, sprays.
- compositions according to the proposed technical solution contain a compound of the general formula (II) in an amount effective to achieve the desired result, and can be administered in unit dosage forms (for example, in solid, semi-solid or liquid forms) containing compounds the proposed technical solution as an active ingredient in a mixture with a carrier or excipient suitable for intramuscular, intravenous, oral, sublingual, inhalation, local, nasal, rectal and vaginal administration.
- the active ingredient may be included in the composition along with commonly used non-toxic pharmaceutically acceptable carriers suitable for the manufacture of solutions, tablets, pills, capsules, dragees, suppositories, emulsions, suspensions, ointments, gels and any other dosage forms.
- the specific dosage level and frequency of drug administration for each particular patient will depend on a large number of factors, including the activity of a particular derivative of fulle rena, metabolic stability and duration of action, rate of excretion, patient age, body weight, general health, gender, drug combinations, as well as the severity of the disease in the individual being treated.
- compositions are formulated according to methods well known in the pharmaceutical art and may contain microcrystalline cellulose or derivatives thereof to provide bulk, alginic acid or sodium alginate as suspending agent an agent, methyl cellulose as a viscosity enhancer, and sweeteners and / or perfumes known in the art.
- such compositions may contain microcrystalline cellulose, calcium phosphate, starch, magnesium stearate and lactose and / or other excipients, binders, diluents, disintegrants, diluents and lubricants known in the art.
- compositions When used in the form of nasal aerosols or by inhalation, such compositions are prepared by methods well known in the field of pharmaceutical formulations, and they can be produced as solutions in physiological saline, using benzoic acid or other suitable preservatives, adsorption promoters to enhance bio-applicability and / or other solubilizing or dispersing agents known in the art.
- Injectable solutions or suspensions may be formulated according to known methods using non-toxic, parenterally acceptable diluents or solvents such as mannitol, 1, 3-butanediol, water, Ringer's solution or isotonic sodium chloride solution or suitable dispersing or wetting and suspending agents, such as sterile, soft, stable oils, including synthetic mono- or diglycerides, or fatty acids, including oleic acid.
- suitable diluents or solvents such as mannitol, 1, 3-butanediol, water, Ringer's solution or isotonic sodium chloride solution or suitable dispersing or wetting and suspending agents, such as sterile, soft, stable oils, including synthetic mono- or diglycerides, or fatty acids, including oleic acid.
- compositions can be prepared by mixing the drug with a non-irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solids at ordinary temperatures but liquefy and / or dissolve in the body cavity with the release of the drug.
- a non-irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solids at ordinary temperatures but liquefy and / or dissolve in the body cavity with the release of the drug.
- compositions When applied topically in the form of ointments, gels, creams, lines, etc. such compositions may be prepared by mixing the active ingredients with an acceptable ointment base.
- Fat, hydrocarbon or hydrophilic bases for example, petroleum jelly, paraffin oil, paraffin, wax, lanolin, polyethylene glycol, etc. can be used as ointment bases.
- Methyl cellulose, sodium salt of carboxymethyl cellulose, hydroxypropyl cellulose, polyethylene glycol or polyethylene oxide, carbopol, polyvinylpyrrolidone, polyvinyl alcohol, etc. can be used as the basis for gels.
- compositions that contain, as an active substance, homo- and hetero-polyamino acid derivatives of fullerene of the formula (II), having activity against herpes virus, hepatitis C virus, influenza viruses of various nature, HIV, as well as antitumor and anti-psoriatic activity.
- Pharmaceutical compositions are in the form of tablets, capsules, ointments, suppositories, solutions, sprays.
- the inventive method allows to obtain various homo- and hetero-polyamino acid derivatives of fullerene depending on the ratio of reagents and process conditions.
- Example 1 Preparation of fullerene polyamino-caproic acid of the formula C 6 o (H3) ⁇ NH (CH2) 5 COO " ⁇ 3 ⁇ NH 3 + (CH 2 ) 5 COOH ⁇ 3.
- the yield of the target product is quantitative with respect to the starting fullerene.
- the compound is a dark brown solid, soluble in dimethyl sulfoxide: water - 1: 200 mixture, sparingly soluble in mixtures of ⁇ 1 ⁇ : ⁇ 2 0 - 1: 1 and DMF- ⁇ 2 0.
- Thermogravimetric analysis of the product shows the presence in the complex of 3 moles of loosely coupled aminocaproic acid, cleaving with decomposition at a temperature of 200 ° C.
- the thermal decomposition of fullerene polyamino acid occurs at a temperature of 345 ° C with the release of fullerene and its oxidation products.
- the amount of solid residue after decomposition of the compound, which is unsubstituted fullerene according to diffraction analysis, corresponds to the ratio C60: amino acid fragment as 1: 6.
- Acid hydrolysis of compound 0, 1 with a molar solution of HC1 leads to the release of aminocaproic acid hydrochloride in an amount of 3 moles per mole of starting material.
- the electronic absorption spectrum of the product does not contain absorption bands of free fullerene.
- the IR spectrum of the product contains absorption bands characteristic of ⁇ -substituted amino acids: -COOH group - 1704 cm “1 , 1658 cm “ 1 , NH 3 + groups - 3100, 2550, 2000 cm “1 , - ⁇ - ⁇ - stretching vibrations of 3300 cm “1 , ⁇ - ⁇ -strain 1552 cm “ 1 , absorption bands ⁇ ⁇ schreib-NH-R-1 104 cm “1 , 930 cm “ 1 , 830 cm “1 .
- Example 2 Obtaining Y-fullerene-y-aminobutyric acid with ⁇ -alanine of the formula: C 6 schreib ( ⁇ ) ⁇ KH (CH 2 ) cCOO " ⁇ s (KH 3 + CH 2 -CH 2 —COOH) 3 .
- the compound is a dark brown solid soluble in dimethyl sulfoxide: water - 1: 200 mixture, sparingly soluble in CH 3 CN: H 2 0 - 1: 1 and DMF-H 2 0 mixtures.
- Thermogravimetric analysis of the product shows the presence in the complex of 3 moles of loosely bound ⁇ -alanine, cleaving at a temperature of 210 ° C.
- the thermal decomposition of the whole complex takes place at a temperature of 335 ° C with the release of fullerene in the amount corresponding to the ratio of C b o ⁇ amino acid fragments as 1: 6.
- the spectra of the product in solutions in dimethyl sulfoxide and in a 0, 1 N aqueous solution of NaOH contain absorption bands in the region of 217, 260, 335 nm, characteristic of fullerene derivatives and do not contain absorption bands of free fullerene.
- the IR spectrum of the compound contains absorption bands characteristic of ⁇ -substituted amino acids and cationic forms of amino acids: —COOH groups “ 1717 cm ” 1 , 1710 cm “1 , 1658 cm ” 1 , groups NH 3 + 3100, 2550, 2000 cm “1, ⁇ - ⁇ -stretching vibrations 3400 cm” 1, NH- stretching vibrations - 3400 cm “1, NH- deformation - 1552 cm” 1, the absorption band of C b-NH-R- 1104 cm “1 930 cm "1 , 830 cm “ 1 .
- Acid hydrolysis of the compound results in the release of glutamine hydrochloride in an amount of 3 moles per mole of the starting material.
- the preparation obtained by the method described in example 1 is named for the preparation Ns 1 (fullerenepolyaminocaproic acid).
- Example 4 Investigation of the activity of the preparation of fullerenpolyaminocaproic acid against human immunodeficiency virus.
- test drug was added to the cells and infected with the virus at a dose of 0.01 TCID 50 / cell.
- Cell cultures were incubated at 37 ° C in an atmosphere with 5% C0 2 and 98% humidity for 4-5 days. The results were taken into account by staining the cells with dye and light microscopy: investigation of the cytopathic effect of the virus (JRC) and virus-induced syncytium formation (syncytium is a conglomerate of several cells with a common cell membrane formed as a result of fusion of their membranes).
- JRC cytopathic effect of the virus
- virus-induced syncytium formation syncytium is a conglomerate of several cells with a common cell membrane formed as a result of fusion of their membranes.
- the degree of cytodestruction was evaluated under a microscope according to the generally accepted four-cross ' system with + or - signs, respectively, according to the number of dead cells in each of the four wells corresponding to one studied parameter.
- Example 5 Investigation of the antiherpetic activity of the preparation of fullerenpolyaminocaproic acid in in vitro experiments. The study was performed by the Research Institute of Virology named after D.I. Ivanovo RAMS, Moscow.
- the study used transplantable monkey kidney cell culture (VERO), obtained from the tissue culture collection of the Institute of Virology. I.D. Ivanovo RAMS; Herpes simplex virus, type 1, strain L 2 , propagated in Vero cells. Cells were infected with the virus at a dose of 100 TCID 50 / 0.2ml and 1000 TCID 50 / 0.2ml.
- VEO transplantable monkey kidney cell culture
- the preparation was initially dissolved in dimethyl sulfoxide (DMSO) in a ratio of 1: 20, and then working concentrations were prepared on the MEM NEEDLE medium.
- DMSO dimethyl sulfoxide
- the activity of the tested samples was evaluated by the degree of protection of cells from the virus-induced cytotoxic effect of HSV using the microscopic method and the MTT method of optical density. The results of the study.
- the toxicity of the substances in the used concentrations, as well as the solvent was studied.
- the preparation at final concentrations of 50 to 1000 mcg / ml are adding to the monolayer VERO cell culture and incubated in an atmosphere of 5.0% C0 2 at 37 ° C for 24-48 hours.
- the cell monolayer was stained with a 0.4% trypan blue solution and examined under a microscope.
- the sample at a concentration of up to 100 ⁇ g / ml did not have a toxic effect on the VERO cell culture; at a concentration of 200 ⁇ g / ml, signs of a toxic effect appear - 25% of the cells are dead. Concentrations of 500 ⁇ g / ml or more are already toxic to Vero cells (Table 3).
- the study of the protective properties of the sample was carried out with one administration schedule — one hour before infection, and with two doses of the virus — 100 TCID 50 and 1000 TCID 50 .
- Example 6 Study of the activity of fullerenepolyaminocaproic acid (preparation No. 1) against influenza virus A / IIV-Moscow / 01/2009 (HlNl) swl.
- the preparation was diluted in DMSO (5 mg of substance + 0.5 ml of DMSO), followed by the addition of 4.5 ml of MEM cell culture medium, thereby obtaining a stock at a concentration of 1.0 mg / ml. Subsequently, wastewater was diluted with MEM medium to working concentrations of 6.5 ⁇ g / ml - 12.5 -25.0 - 50.0 - 100 ⁇ g / ml.
- the antiviral activity of the substances was determined by reducing the reproduction of the influenza virus in the MDCK cell culture detected by ELISA.
- MDSK cells were grown in 96-well plates to a complete monolayer, washed from the growth medium, and the substances were added at a double concentration in 100 ⁇ l of MEM medium.
- Virus infection in a working dose of 100-1000 TTsID 50 was carried out in two modes: 2 hours after the introduction of substances and at the same time.
- the plates were incubated in a thermostat with C0 2 for 24 hours at 37 ° C. After incubation, the medium was removed and the cells were fixed with 80% acetone in PBS for 15 minutes, dried well and ELISA was performed by adsorption of specific reagents — monoclonal antibodies, conjugate and substrate (orthophenylenediamine).
- the reaction was taken into account by optical density at 492 nM on a spectrophotometer Biocom firms. Each virus dilution was examined in 3 replicates, for which the average optical density (OD) was calculated. The percentage of inhibition was determined as the ratio between the difference between the OD of experience and the OD of cell control, divided by the difference between the OD of the viral control and the OD of the cell control, multiplied by 100%. Based on the data obtained, the values of the minimum concentration of the substance causing 50.0% inhibition of viral reproduction (MIC 50 ) were determined.
- Example N-? 7 The study of the antiviral activity of fullerenpolyaminocaproic acid (preparation No. 1) in a model of influenza pneumonia in mice. The studies were carried out at the Center for Chemistry of Medicines (TsHLS-VNIHFI), Moscow.
- influenza virus A / Aichi / 2/69 H3N2
- H3N2 H3N2
- This virus is widely used to determine the effectiveness of antiviral drugs on the model of influenza pneumonia in mice and was obtained from the Museum of Viral Strains and Cell Cultures of the Research Institute of Virology RAMS.
- the mice were infected intranasally with the allantoic virus, after the onset of signs of the disease, they were killed and, under sterile conditions, lung tissue homogenate was obtained. Further, this homogenate was used to infect 10-day-old chicken embryos from which the allantoic virus was obtained and, after titration on its mice, was used to infect animals.
- mice Females weighing 12-14 g were obtained from the Andreevka nursery (Moscow region) and kept on a standard diet under regulated vivarium conditions.
- mice Pre-weighed mice (non-linear females, average weight 12-14 g) were infected intranasally under mild ether anesthesia with the influenza virus A / Aichi / 2/69 (H3N2) (10 LD 50 in 100 ⁇ l).
- H3N2 influenza virus A / Aichi / 2/69
- LD 50 was determined by titration of the allantoic virus in the same mice that These were then used in the main experiment.
- the following treatment regimen was used with the studied drug: 24 hours before infection, 1 hour before infection, 24 hours later, and then once a day, 24 hours for 5 days.
- a single-use insulin syringe with a special needle (lavage) was used, each dose was administered in a volume of 100 ⁇ l.
- each dose was also administered in a volume of 100 ⁇ l.
- the viral control group consisted of 10 mice infected with the virus but not treated with the drugs. Also in the experiment there were two groups of 10 uninfected mice, which were injected intraperitoneally and intramuscularly with 100 ⁇ l of 1.5% DMSO, which was used as a solvent for the preparations. In the remaining groups, there were also initially 10 animals. The treated and control animals were monitored daily; in the first 5 days after infection, the mice were weighed every day, then every other day. The chemotherapeutic activity of the drug in a mouse influenza pneumonia model was evaluated according to three criteria: protection against fatal viral infection, increase in average life expectancy, and decrease in weight loss in the animals treated with the drug compared to the control group.
- the treatment with fullerenaminocaproic acid was effective, reducing the mortality of mice from influenza pneumonia and weight loss, and increasing the average life expectancy compared with the viral control.
- the effectiveness of this treatment depended on the dose of the drug and the treatment method.
- the results are presented in tables 10 - 1 1.
- the most effective in all three parameters was the intramuscular treatment of fullerenpolyaminocaproic acid, which prevented the death of 60-70% of infected animals and their weight loss at doses of 100 and 200 mg / kg / day , and also increased their life expectancy by almost 2 times.
- Intraperitoneal treatment with fullerenpolyaminocaproic acid was effective only at doses of 50 and 100 mg / kg / day.
- Example N2 8. Study of the antitumor effect of fullerenpolyaminocaproic acid (preparation No. 1) in case of transplantable tumors of leukemia L1210, breast adenocarcinoma Ca-755 and Lewis carcinoma.
- mice DBA / 2 mice with transplanted L1210 leukemia cells.
- the age of the mice is 6-8 weeks, weight 19-25 g.
- mice males of the C 57 BL / 6j line with transplanted C-755 cells The age of the mice is 6-8 weeks, weight 19-25 g.
- mice males of the C 57 BL / 6j line with 3LL transplanted cells Mice males of the C 57 BL / 6j line with 3LL transplanted cells.
- mice The age of the mice is 6-8 weeks, weight 18-24 g.
- Table 13 shows the average life expectancy of animals with transplantable tumors of L1210 leukemia and the control group, as well as data on the increase in life expectancy compared to the control group in%.
- mice of the control group with transplanted tumor cells of leukemia L1210 were 6.0 ⁇ 0.21 days.
- the introduction of the drug significantly increased the life expectancy of mice to 10.7 ⁇ 0.37 days and 10.60 ⁇ 0.37 days, the percentage increase in duration life compared with the control was 78.33% and 76.67% for doses of the drug 100 mg / kg and 200 mg / kg, respectively, however, the differences between the experimental groups were statistically unreliable.
- mice receiving the study drug was significantly less than in the control group, and in animals receiving the study drug in a dose of 250 mg / kg, the average weight gain was significantly lower (1.5 times) compared to - Niyu with such an indicator in animals treated with the drug at a dose of 100 mg / kg.
- the obtained results allow us to conclude that the drug exhibits a pronounced anti-tumor effect and inhibits the growth of tumor cells of L1210 leukemia in mice, which was manifested in a significant increase in life expectancy (78.33% and 76.67%) for doses of 100 and 250 mg / kg and significant inhibition of accumulation of ascites in experimental animals (78-43%). Signs of intoxication against the background of the administration of the study drug were not registered. An analysis of the data revealed significant differences between the dose of 100 mg / kg and the dose of 250 mg / kg - an increase in the dose leads to a significant decrease in ascites accumulation in experimental animals. For other indicators, the contrast (the difference between the means for the groups receiving different doses of the study drug) was at the level of errors caused by the natural spread of data.
- Table 16 shows the average life expectancy of animals with transplantable tumors of mammary adenocarcinoma Ca-755 and the control group, as well as data on the increase in life expectancy compared to the control group in%.
- mice in the control group with inoculated tumor cells with mammary adenocarcinoma tumors Ca-755 was 37.9 + 0.74 days /
- the obtained results allow us to conclude that the drug exhibits a pronounced anti-tumor effect and inhibits the growth of tumor cells of mammary adenocarcinoma Ca-755 in mice, which was manifested in a significant increase in life expectancy (89.71% and 93.67%) for doses of 100 and 250 mg / kg. Signs of intoxication against the background of the administration of the study drug were not registered.
- tumors developed in 21 of 26 mice (80.8%) the first tumors were registered on the 7th day after inoculation and were registered up to 40 days.
- the first tumors in the group with the drug at a dose of 100 mg / kg were recorded on the 7th day after inoculation and were recorded up to 60 days; in the group with the drug at a dose of 250 mg / kg were recorded on day 8 after inoculation and were recorded up to 60 days.
- the drug had a pronounced antitumor effect on the development of Lewis lung carcinoma; the percentage of inhibition in the drug group - 100 mg / kg compared with the control group for 10-17 days was reliably 71.77% and 58.5%, in the drug group - 250 mg / kg compared with the control group at 10- 17 days - 84.37% and 54.2%, respectively.
- Table 17 shows the effect of the drug on the growth of Lewis carcinoma, analyzed the timing of the tumor reaching a size of 500 mm; in the control group, this indicator ranged from 12 to 20 days, and in the experimental groups from 17 to 28 days. As can be seen from this table, the drug significantly increased this indicator by 22-27% compared with the control.
- mice in the control group occurred as a result of the progression of tumor growth of the main focus, as well as due to extensive metastatic lung damage.
- the individual life expectancy of mice in the control group ranged from 28 to 39 days, in groups with the drug from 51 to 60 days.
- Table 18 shows the effect of the drug on the average life expectancy of mice after tumor inoculation. As can be seen from table 18, the drug significantly increased the average life expectancy by about 70% compared with the control group, the difference between the experimental groups is not statistically significant.
- the antiherpetic activity of a sample of fullerene polyaminocanoic acid in a Vero cell culture with an infectious dose of herpes virus is 100 TCID 50 / 0.2 ml
- influenza virus in the culture of
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2013008545A MX354436B (es) | 2011-02-01 | 2012-02-06 | Derivados de homo- y hetero-poliaminoácidos de fulereno c60, método para producir los mismos, y composiciones farmacéuticas con base en dichos derivados. |
ES12741829.1T ES2582872T3 (es) | 2011-02-01 | 2012-02-06 | Derivados homo- y hetero-poliaminoácidos de fullereno C60, método para la producción de los mismos, y composiciones farmacéuticas basadas en dichos derivados |
CA2810507A CA2810507A1 (en) | 2012-02-06 | 2012-02-06 | Homo- and hetero-polyamino-acid derivatives of fullerene c60, method for producing same, and pharmaceutical compositions based on said derivatives |
EP12741829.1A EP2674415B1 (en) | 2011-02-01 | 2012-02-06 | Homo- and hetero-polyamino-acid derivatives of fullerene c60, method for producing same, and pharmaceutical compositions based on said derivatives |
US13/820,769 US9221746B2 (en) | 2011-02-01 | 2012-02-06 | Homo- and hetero-polyamino-acid derivatives of fullerene C60, method for producing same, and pharmaceutical compositions based on said derivatives |
AU2012212707A AU2012212707B2 (en) | 2011-02-01 | 2012-02-06 | Homo- and hetero-polyamino-acid derivatives of fullerene C60, method for producing same, and pharmaceutical compositions based on said derivatives |
BR112013012910-7A BR112013012910A2 (pt) | 2011-02-01 | 2012-02-06 | Derivados de fulereno de homo e heteropoli aminoácidos c60, método para a produção dos mesmos e composições famacêuticas com base nos referidos derivados |
CN201280003407.9A CN103347849B (zh) | 2012-02-06 | 2012-02-06 | 富勒烯с60的均聚氨基酸和杂多氨基酸衍生物、其制备方法和基于该衍生物的药物组合物 |
EA201201448A EA020801B1 (ru) | 2011-02-01 | 2012-02-06 | Гомо- и гетерополиаминокислотные производные фуллерена с, способ их получения и фармацевтические композиции на их основе |
AP2013007072A AP4014A (en) | 2011-02-01 | 2012-02-06 | Homo- and hetero-polyamino-acid derivatives of fullerene c60, method for producing same, and pharmaceutical compositions based on said derivatives c60 |
UAA201301251A UA110345C2 (en) | 2011-02-01 | 2012-06-02 | Homo- and heteropolyaminoacid derivatives of fullerene c60, and method for their pharmaceutical compositions on their basis |
ZA2013/03447A ZA201303447B (en) | 2011-02-01 | 2013-05-13 | Homo-and hetero-polyamino-acid derivatives of fullerene c60, method for producing same, and pharmaceutical compositions on said derivatives |
IL226736A IL226736A (en) | 2011-02-01 | 2013-06-04 | Homo- and hetero derivatives of Fullerene Polyamino Acids 60c, Methods of Preparation and Pharmaceutical Preparations Containing These Derivatives |
HK14103544.9A HK1190386A1 (zh) | 2011-02-01 | 2014-04-14 | 富勒烯 的均聚和雜聚氨基酸衍生物,其生產方法以及基於該衍生物的藥物組合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011103574 | 2011-02-01 | ||
RU2011103574/04A RU2458914C1 (ru) | 2011-02-01 | 2011-02-01 | Гомо- и гетеро-полиаминокислотные производные фуллерена c60, способ их получения и фармацевтические композиции на их основе |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012105872A1 true WO2012105872A1 (ru) | 2012-08-09 |
Family
ID=46602956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2012/000062 WO2012105872A1 (ru) | 2011-02-01 | 2012-02-06 | Гомо- и гетеро-полиаминокислотные производные фуллерена с60, способ их получения и фармацевтические композиции на их основе |
Country Status (14)
Country | Link |
---|---|
US (1) | US9221746B2 (ru) |
EP (1) | EP2674415B1 (ru) |
AP (1) | AP4014A (ru) |
AU (1) | AU2012212707B2 (ru) |
BR (1) | BR112013012910A2 (ru) |
EA (1) | EA020801B1 (ru) |
ES (1) | ES2582872T3 (ru) |
HK (1) | HK1190386A1 (ru) |
IL (1) | IL226736A (ru) |
MX (1) | MX354436B (ru) |
RU (1) | RU2458914C1 (ru) |
UA (1) | UA110345C2 (ru) |
WO (1) | WO2012105872A1 (ru) |
ZA (1) | ZA201303447B (ru) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103450486A (zh) * | 2013-05-14 | 2013-12-18 | 成立 | 双亲有机聚富勒烯树状分子交联的聚阳离子聚合物凝胶物质及其制备方法 |
CN104478886A (zh) * | 2014-12-30 | 2015-04-01 | 郑州大学 | 一种富勒烯双加成氨基酸及其合成方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2162819C2 (ru) | 1999-01-05 | 2001-02-10 | Тверской государственный технический университет | Способ получения водорастворимых производных фуллеренов |
US6204391B1 (en) | 1994-01-24 | 2001-03-20 | The Regents Of The University Of California | Water soluble fullerenes with antiviral activity |
RU2236852C1 (ru) | 2003-06-23 | 2004-09-27 | Закрытое акционерное общество "ДЕСКО" | Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций |
WO2005070827A2 (en) | 2004-01-14 | 2005-08-04 | William Marsh Rice University | Fullerene based amino acids |
RU2316320C1 (ru) * | 2006-06-19 | 2008-02-10 | Лев Давидович Раснецов | Противовирусное средство |
WO2009000203A1 (fr) | 2007-06-28 | 2008-12-31 | Huawei Technologies Co., Ltd. | Procede de transmission de donnees, entrelaceur et dispositif de communication |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030027870A1 (en) * | 2001-05-15 | 2003-02-06 | Wilson Stephen R. | Fullerene derivatives that modulate nitric oxide synthase and clamodulin activity |
RU2196602C1 (ru) * | 2002-01-22 | 2003-01-20 | Закрытое акционерное общество "ДЕСКО" | Средство для ингибирования вич и цмв-инфекций и способ их ингибирования |
RU2213048C1 (ru) * | 2002-07-08 | 2003-09-27 | Закрытое акционерное общество "ДЕСКО" | Способ получения водорастворимых солей аминокислотных производных фуллерена |
RU2213049C1 (ru) * | 2002-07-08 | 2003-09-27 | Закрытое акционерное общество "ДЕСКО" | Способ получения водорастворимых аминокислотных производных фуллерена |
CA2687557A1 (en) | 2007-06-19 | 2008-12-31 | Institute Of Problems Of Chemical Physics Ras (Ipcp Ras) | Polyfunctional fullerene c60 amino acid derivatives |
-
2011
- 2011-02-01 RU RU2011103574/04A patent/RU2458914C1/ru active
-
2012
- 2012-02-06 US US13/820,769 patent/US9221746B2/en active Active
- 2012-02-06 EP EP12741829.1A patent/EP2674415B1/en not_active Not-in-force
- 2012-02-06 BR BR112013012910-7A patent/BR112013012910A2/pt not_active IP Right Cessation
- 2012-02-06 AU AU2012212707A patent/AU2012212707B2/en not_active Ceased
- 2012-02-06 WO PCT/RU2012/000062 patent/WO2012105872A1/ru active Application Filing
- 2012-02-06 EA EA201201448A patent/EA020801B1/ru unknown
- 2012-02-06 ES ES12741829.1T patent/ES2582872T3/es active Active
- 2012-02-06 MX MX2013008545A patent/MX354436B/es active IP Right Grant
- 2012-02-06 AP AP2013007072A patent/AP4014A/en active
- 2012-06-02 UA UAA201301251A patent/UA110345C2/ru unknown
-
2013
- 2013-05-13 ZA ZA2013/03447A patent/ZA201303447B/en unknown
- 2013-06-04 IL IL226736A patent/IL226736A/en active IP Right Grant
-
2014
- 2014-04-14 HK HK14103544.9A patent/HK1190386A1/zh not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204391B1 (en) | 1994-01-24 | 2001-03-20 | The Regents Of The University Of California | Water soluble fullerenes with antiviral activity |
RU2162819C2 (ru) | 1999-01-05 | 2001-02-10 | Тверской государственный технический университет | Способ получения водорастворимых производных фуллеренов |
RU2236852C1 (ru) | 2003-06-23 | 2004-09-27 | Закрытое акционерное общество "ДЕСКО" | Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций |
WO2005070827A2 (en) | 2004-01-14 | 2005-08-04 | William Marsh Rice University | Fullerene based amino acids |
RU2316320C1 (ru) * | 2006-06-19 | 2008-02-10 | Лев Давидович Раснецов | Противовирусное средство |
WO2009000203A1 (fr) | 2007-06-28 | 2008-12-31 | Huawei Technologies Co., Ltd. | Procede de transmission de donnees, entrelaceur et dispositif de communication |
Non-Patent Citations (10)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103450486A (zh) * | 2013-05-14 | 2013-12-18 | 成立 | 双亲有机聚富勒烯树状分子交联的聚阳离子聚合物凝胶物质及其制备方法 |
CN103450486B (zh) * | 2013-05-14 | 2016-09-14 | 成立 | 双亲有机聚富勒烯树状分子交联的聚阳离子聚合物凝胶物质及其制备方法 |
CN104478886A (zh) * | 2014-12-30 | 2015-04-01 | 郑州大学 | 一种富勒烯双加成氨基酸及其合成方法 |
Also Published As
Publication number | Publication date |
---|---|
ES2582872T3 (es) | 2016-09-15 |
MX354436B (es) | 2018-03-06 |
AU2012212707A1 (en) | 2013-03-07 |
EP2674415B1 (en) | 2016-04-20 |
HK1190386A1 (zh) | 2014-07-04 |
UA110345C2 (en) | 2015-12-25 |
BR112013012910A2 (pt) | 2020-03-31 |
EA201201448A1 (ru) | 2013-03-29 |
US9221746B2 (en) | 2015-12-29 |
US20130165691A1 (en) | 2013-06-27 |
IL226736A (en) | 2016-05-31 |
AU2012212707B2 (en) | 2014-03-20 |
AP2013007072A0 (en) | 2013-08-31 |
MX2013008545A (es) | 2016-09-08 |
EP2674415A1 (en) | 2013-12-18 |
EP2674415A4 (en) | 2014-09-10 |
AP4014A (en) | 2017-01-25 |
RU2458914C1 (ru) | 2012-08-20 |
ZA201303447B (en) | 2014-01-29 |
EA020801B1 (ru) | 2015-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7030093B2 (ja) | オキサチアジン様化合物を作製する方法 | |
CN103347849B (zh) | 富勒烯с60的均聚氨基酸和杂多氨基酸衍生物、其制备方法和基于该衍生物的药物组合物 | |
US8450318B2 (en) | Method to treat infections using anti-infective agents | |
RU2458914C1 (ru) | Гомо- и гетеро-полиаминокислотные производные фуллерена c60, способ их получения и фармацевтические композиции на их основе | |
US20130109663A1 (en) | N6-(ferrocenmethyl)quinazolin-2,4,6-triamina (h2) and the derivatives and prodrugs thereof as antileishmanial, antiprotozoal, antiparasitic and antimicrobial agents | |
US7732433B2 (en) | Biologically active complex | |
CA2810515C (en) | Hydrated n-fullerene amino acids, method for producing the latter, and pharmaceutical compositions on the basis thereof | |
DK2851368T3 (en) | COMPLEX COMPOUNDS OF GERMANIUM, PROCEDURES FOR PRODUCING THEREOF, AND PHARMACEUTICALS | |
RU2458046C1 (ru) | Гидратированные n-фуллерен-аминокислоты, способ их получения и фармацевтические композиции на их основе | |
AU679676B2 (en) | Ion pairs of hypericin compounds having antiviral activity | |
RU2820633C1 (ru) | Производное индол-3-карбоновой кислоты, обладающее противовирусной активностью в отношении sars-cov-2 | |
OA16420A (en) | Homo-andhetero-polyamino-acid derivatives of fullerence C60, method for producing same, and pharmaceutical compositions based on said derivatives. | |
JP5302393B2 (ja) | 新規ジアリールヘパトノイド系化合物及びその用途 | |
OA16498A (en) | Hydrated N-fullerene amino acids, method for producing the latter, and pharmaceutical compositions on the basis thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201280003407.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12741829 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201201448 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012741829 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2810507 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13820769 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2012212707 Country of ref document: AU Date of ref document: 20120206 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201301251 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/008545 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013012910 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112013012910 Country of ref document: BR Free format text: APRESENTE TRADUCAO SIMPLES DA CERTIDAO DE DEPOSITO DA PRIORIDADE NO PAIS DE ORIGEM OU DECLARACAO ASSINADA, AMBAS CONTENDO TODOS OS DADOS IDENTIFICADORES DA PRIORIDADE CONFORME ART. 16, 2O, DA LPI. |
|
ENP | Entry into the national phase |
Ref document number: 112013012910 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130524 |